Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Receivables (2019 - 2025)

Nanobiotix has reported Receivables over the past 7 years, most recently at $5.0 million for Q4 2025.

  • For Q4 2025, Receivables fell 22.1% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, down 22.1%, while the annual FY2025 figure was $5.0 million, 22.1% down from the prior year.
  • Receivables for Q4 2025 was $5.0 million at Nanobiotix, up from $2.1 million in the prior quarter.
  • Over five years, Receivables peaked at $6.4 million in Q4 2024 and troughed at $253959.5 in Q2 2022.
  • A 5-year average of $3.1 million and a median of $2.9 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: soared 367.37% in 2023 and later tumbled 38.13% in 2025.
  • Year by year, Receivables stood at $3.9 million in 2021, then fell by 24.97% to $2.9 million in 2022, then decreased by 13.8% to $2.5 million in 2023, then surged by 155.41% to $6.4 million in 2024, then dropped by 22.1% to $5.0 million in 2025.
  • Business Quant data shows Receivables for NBTX at $5.0 million in Q4 2025, $2.1 million in Q2 2025, and $6.4 million in Q4 2024.